Floatz logo

Plixorafenib

BRAF-mutated Tumors

Fore BiotherapeuticsSmall moleculePhase 2Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

927 Active assets in the BRAF-mutated Tumors cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

Plixorafenib is also rated in:

malignant gliomaDormant
CCC
Indicative ·
50 / 100
View asset →
Cancer Harboring BRAF AlterationsDormant
CCC
Indicative ·
50 / 100
View asset →
low grade gliomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →